Apellis Pharmaceuticals, Inc. (APLS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-01

Key Insights

Caroline Baumal, Chief Medical Officer at Apellis Pharmaceuticals, executed a charitable contribution of 900 shares on April 29, 2026, indicating a non-monetary transaction rather than insider selling pressure.
Following the transaction, Baumal maintains beneficial ownership of 86,525 shares, demonstrating continued significant stake in the company despite the charitable donation.
The filing includes an Employee Stock Purchase Plan (ESPP) purchase of 898 shares completed on April 30, 2026, suggesting regular participation in company equity programs by senior management.
The use of an attorney-in-fact (David Watson) to execute this filing is standard practice for senior executives and does not indicate any irregularities or concerns.

Want the newest filings?

This analysis covers the filing from 2026-05-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-08

The reporting person, Stephanie Monaghan O'Brien, acquired 5,750 shares of Apellis Pharmaceuticals, Inc. (APLS) common stock indirectly through a spousal account, indicating potential positive insider sentiment.
O'Brien already held 25,666 shares of APLS common stock directly, suggesting a meaningful investment in the company.
The transaction was a distribution of shares from a trust to the spouse's account, which did not change the reporting person's overall beneficial ownership.

Filed: 2026-02-05

Insider Cedric Francois, the CEO of Apellis Pharmaceuticals, exercised a stock option for 8,840 shares at $3.76 per share, increasing his direct ownership to 490,837 shares.
Francois also holds indirect ownership of the company's shares through various trusts, including The Cedric Francois Irrevocable Trust of 2023 (472,065 shares), The Francois Grossi Trust (300,000 shares), and The Francois-DuBois Educational Trust (234,411 shares).
The option exercise suggests Francois's continued commitment to and confidence in Apellis Pharmaceuticals, as he increases his direct and indirect stake in the company.

Filed: 2026-01-30

Leslie Meltzer, the Chief Research and Development Officer of Apellis Pharmaceuticals, acquired 45,220 shares of the company's common stock through a restricted stock unit award. This indicates their confidence in the company's future prospects.
The restricted stock units vest 25% annually over four years, aligning Meltzer's incentives with long-term shareholder value creation.
The filing does not indicate any sales or dispositions of Apellis shares by Meltzer, suggesting they are holding their position and maintaining a positive outlook on the company.

Filed: 2026-01-30

Cedric Francois, the CEO of Apellis Pharmaceuticals, Inc. (APLS), has been granted 195,952 restricted stock units (RSUs) that vest over 4 years, indicating the company's commitment to retaining key leadership.
Francois also holds significant indirect ownership in APLS through various trusts, totaling over 1.3 million shares, demonstrating his long-term alignment with shareholders.
The insider ownership structure suggests a high level of management involvement and potential for continued strategic direction from the CEO.

Filed: 2026-01-30

The reporting person, David O. Watson, was granted 55,986 restricted stock units that vest over 4 years, indicating potential long-term commitment to the company.
Watson holds direct ownership of 144,517 common shares, as well as indirect ownership through custodial accounts and trusts, suggesting substantial personal investment in Apellis Pharmaceuticals.
The reporting covers insider transactions, which can provide insight into management's confidence and strategic direction for the company.

Filed: 2026-01-30

Timothy Sullivan, the Chief Financial Officer, acquired 58,140 shares of Apellis Pharmaceuticals through a restricted stock unit award, increasing his direct ownership to 152,041 shares.
Sullivan also has an indirect beneficial ownership of 60,396 shares held by The Timothy E Sullivan Irrevocable Trust of 2023, indicating a significant insider ownership position.
The restricted stock unit award vests 25% annually over four years, aligning Sullivan's incentives with long-term shareholder value creation.

Filed: 2026-01-30

Nur Nicholson, the Chief Technical Officer of Apellis Pharmaceuticals, Inc., received a Restricted Stock Unit award of 45,220 shares on January 28, 2026, vesting 25% annually over four years.
This award indicates Nicholson's continued commitment to the company and aligns his interests with those of shareholders.
The insider transaction provides insight into the company's leadership and their confidence in the future performance of Apellis Pharmaceuticals.

Filed: 2026-01-30

The reporting person, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, Inc., has acquired 25,840 shares of the company's common stock in the form of a restricted stock unit (RSU) award.
The RSU award vests 25% annually over four years from the grant date of January 28, 2026, subject to continued service, indicating the company's commitment to retaining and incentivizing its key executive.
The transaction represents an insider buying activity, which can be viewed positively by investors as a sign of management's confidence in the company's prospects.

Filed: 2026-01-30

The reporting person, Mark DeLong, was granted 36,606 restricted stock units (RSUs) on January 28, 2026, vesting 25% annually over four years, indicating an ongoing commitment to the company.
The reporting person's direct beneficial ownership of Apellis Pharmaceuticals, Inc. (APLS) common stock increased from 78,353 shares to 114,959 shares, suggesting increased alignment with shareholders.
The grant of RSUs to a key executive, the Chief Business & Strategic Officer, signals continued investment in the company's leadership and strategic direction.

Filed: 2026-01-30

The reporting person, James George Chopas, received a grant of 16,150 restricted stock units (RSUs) on January 28, 2026, which vest 25% annually over four years subject to continued service.
This RSU grant increases Chopas' beneficial ownership of Apellis Pharmaceuticals' common stock to 65,955 shares, indicating his continued commitment to the company.
The timing and amount of this RSU award suggest that Chopas, as VP/Chief Accounting Officer, is being incentivized and rewarded for his contributions to the company.

Filed: 2026-01-30

Kelley Boucher, the Chief People Officer, has received a restricted stock unit (RSU) award of 30,146 shares, vesting over 4 years, indicating the company's commitment to retaining and incentivizing key personnel.
The direct ownership of Kelley Boucher has increased to 127,804 shares, suggesting their alignment with the company's long-term success.
This RSU grant is part of the company's equity compensation program, which is likely used to attract, retain, and motivate talented employees like Kelley Boucher.

Filed: 2026-01-23

Nur Nicholson, the Chief Technical Officer of Apellis Pharmaceuticals, sold 7,725 shares of common stock on January 22, 2026 at an average price of $21.7654 to cover tax withholding on the release of Restricted Stock Units.
Nicholson's remaining beneficial ownership of Apellis shares is 71,118, indicating he continues to have a significant stake in the company.
The sale of shares to cover taxes is a routine transaction and does not necessarily indicate a change in Nicholson's long-term outlook on the company.

Filed: 2026-01-23

The reporting person, Caroline Baumal, sold 2,797 shares of Apellis Pharmaceuticals, Inc. (APLS) common stock at $21.7654 per share to cover tax withholding on the release of restricted stock units.
The sale represents a small fraction of Baumal's total beneficial ownership of 86,527 shares, suggesting the transaction was routine in nature.
Insider selling can signal a bearish sentiment, but the small size of this transaction and Baumal's continued substantial ownership indicate it may not be a significant signal for the company's prospects.

Filed: 2026-01-23

James Chopas, the VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc., sold 2,064 shares of common stock to cover tax withholding on restricted stock units that vested.
The sale transaction occurred on January 22, 2026 at an average price of $21.7654 per share, reducing Chopas's direct beneficial ownership to 49,805 shares.
This insider sale could indicate the officer's confidence in the stock price or a need for personal liquidity, and investors may want to monitor any further trading activity by Chopas and other insiders.

Filed: 2026-01-23

The reporting person, Mark Jeffrey DeLong, is the Chief Business & Strategy Officer of Apellis Pharmaceuticals, Inc. and has sold 3,371 shares of the company's common stock to cover tax withholding on the release of restricted stock units.
The sale of shares by an insider, even to cover taxes, can be seen as a potential sign of insider sentiment and may impact investor perceptions of the company's outlook.
Investors should monitor insider trading patterns and the context around such transactions to assess the broader implications for the company's performance and management's confidence in its future prospects.

Filed: 2026-01-23

Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, sold 5,928 shares of the company's common stock at an average price of $21.7654 per share.
The sale was made to cover tax withholding on the vesting of 5,928 restricted stock units (RSUs) on January 21, 2026.
After the transaction, Deschatelets still holds 1,151,382 shares of Apellis Pharmaceuticals, indicating his continued ownership and commitment to the company.

Filed: 2026-01-23

The CEO of Apellis Pharmaceuticals, Cedric Francois, sold 27,192 shares of the company's common stock on January 22, 2026 at an average price of $21.7654 per share. This represents a significant insider sale, suggesting potential concerns or liquidity needs.
Cedric Francois, the CEO, also holds significant indirect beneficial ownership in the company through various trust structures, including The Cedric Francois Irrevocable Trust of 2023, The Francois Grossi Trust, and The Francois-DuBois Educational Trust. This indicates a high level of personal investment and alignment with the company's long-term success.
The sale of shares by the CEO to cover tax withholding on the release of restricted stock units (RSUs) is a common practice and may not necessarily indicate a broader sell-off or loss of confidence in the company's prospects.

Filed: 2026-01-23

The reporting person, Timothy Eugene Sullivan, is the Chief Financial Officer of Apellis Pharmaceuticals, Inc. and is disposing of 10,287 shares of common stock to cover tax withholding on restricted stock units.
The reporting person indirectly owns 60,396 shares of Apellis Pharmaceuticals through The Timothy E Sullivan Irrevocable Trust of 2023, which he has a pecuniary interest in.
The reported transaction does not indicate any significant changes in the reporting person's overall beneficial ownership of Apellis Pharmaceuticals shares.

Other reports for Apellis Pharmaceuticals, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.